News

Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Dec 22, 2020

Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection Learn More

Dec 21, 2020

Practical Dermatology

For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2 Learn More

Dec 16, 2020

Business Wire

Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville Learn More

Oct 20, 2020

Neurology Live

DaxibotulinumtoxinA Meets Primary End Point in Cervical Dystonia Study Learn More

Aug 26, 2020

Modern Aesthetics

Revance Commercial Infrastructure to Roll Out RHA Collection of Dermal Fillers Learn More

Aug 25, 2020

Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers Learn More

Jul 29, 2020

Dustin S. Sjuts of Revance Therapeutics: Five Things You Need To Know To Succeed In The Modern Beauty Industry Learn More

Jul 27, 2020

Neurology Live

DaxibotulinumtoxinA Aims to Be Next Big Post-Stroke Spasticity Treatment Learn More

Jul 23, 2020

Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices Learn More

Jun 30, 2020

Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection Learn More

Jun 30, 2020

Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow’s Feet, Respectively Learn More

Job Opportunities

Do you have what it takes to join our team? Check out our Careers page and find out.

Search Jobs

Latest News:

Job Opportunities

Aesthetics

Therapeutics

Investors

Company

Careers